Physician profile
Collin Mcgrath
NPI 1447922521
$3,862.90
in general payments reported to CMS, 2019-2025
23 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.39 · 2022: $756 · 2023: $1,439 · 2024: $1,133 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.99 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $385.51 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $369.50 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $362.58 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $295.78 | 2022-2025 | Auvelity |
| Alkermes, INC. | $291.61 | 2022-2025 | Aristada, Lybalvi |
| Neuronetics, INC. | $222.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $204.71 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $189.39 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $174.80 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.24 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $111.79 | 2022-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $106.13 | 2023-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $89.42 | 2022-2024 | Trintellix |
| Tempus Ai, INC | $88.42 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $79.09 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Almatica Pharma LLC | $78.90 | 2022-2024 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $55.34 | 2021-2022 | |
| Lundbeck LLC | $32.79 | 2024 | Rexulti |
| Tris Pharma INC | $29.90 | 2025 | Dyanavel Xr |
| Indivior INC. | $22.47 | 2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $16.41 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $16.39 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.